This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
by Debanjana Dey
Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.
Should You Continue to Hold Prestige Consumer Stock in Your Portfolio?
by Zacks Equity Research
PBH rides strong on e-commerce gains and brand innovations, but debt load and forex risks cast a shadow on future growth.
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $55.25, denoting a -2.83% change from the preceding trading day.
Bruker Stock Set to Gain From Acquisition of Austria's biocrates
by Zacks Equity Research
BRKR strengthens its MS-based metabolomics platform with the biocrates deal, boosting investor sentiment.
Markets Flat on No Economic or Trade News; Apple Flops at WWDC
by Mark Vickery
We saw no new trade deals made today, though market participants remain positive that they will be forthcoming.
Why Hims & Hers Health (HIMS) Might be Well Poised for a Surge
by Zacks Equity Research
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
PEN Stock Rises Following the Launch of Ruby XL System
by Zacks Equity Research
Penumbra launches FDA-cleared Ruby XL System to bring advanced coil technology to high-flow embolization procedures.
HIMS' Buyouts Fuel International Expansion & Digital Health Innovation
by Zacks Equity Research
Hims & Hers accelerates European growth with new ZAVA acquisition, adding localized care and lab testing innovation.
Omnicell (OMCL) Up 27% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
by Zacks Equity Research
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
HIMS Stock Falls Despite Latest Deal to Expand International Footprint
by Zacks Equity Research
Hims & Hers is set to acquire ZAVA to launch in Germany, France and Ireland, deepening its personalized digital health push.
Why Is Hims & Hers Health (HIMS) Up 10.6% Since Last Earnings Report?
by Zacks Equity Research
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Continue to Hold Labcorp Stock in Your Portfolio?
by Zacks Equity Research
LH's growth focus and financial strength look promising, but can it navigate rising competition and macro headwinds?
Zacks.com featured highlights EverQuote, Hims & Hers Health and Sprouts Farmers Market
by Zacks Equity Research
EverQuote, Hims & Hers, and Sprouts shine with standout earnings surprises and strong DuPont-driven fundamentals.
TMO Launches Next-Generation Mass Spectrometers: Stock to Gain?
by Zacks Equity Research
Thermo Fisher debuts two advanced MSs, Orbitrap Astral Zoom and Orbitrap Excedion Pro, to accelerate precision medicine and drug discovery breakthroughs.
The Bull Market is Back: 3 Stocks to Buy Now (HIMS, APP, META)
by Ethan Feller
Hims & Hers Health, AppLovin and Meta Platforms all boast a litany of bullish catalysts driving their stock prices higher.
Why Hims & Hers Health, Inc. (HIMS) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances
by Zacks Equity Research
QIAGEN expands the oncology portfolio with new MRD testing alliances, setting the stage for personalized cancer care and stock growth.
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
by Sanghamitra Saha
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
LH Stock Rises Following the Expansion of Precision Oncology Portfolio
by Zacks Equity Research
Labcorp expands its precision oncology lineup with new cancer tests and a global diagnostic tool.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Charles River Stock May Gain From Extended CHDI Research Deal on HD
by Zacks Equity Research
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
Should JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for BBSC
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Hims & Hers vs. Amwell: Which Telehealth Stock Is the Better Buy?
by Debanjana Dey
HIMS targets personalized, AI-powered care with bold obesity moves, while AMWL bets on system-wide integration via Converge and top-tier health alliances. Who wins? Let's see.